65,437 trials
Peritoneal Neoplasms · Intestinal Obstruction · Carcinomatosis
Primary: Number of Participants With Treatment Success From Day 10 to Day 13 — 12; 9; 19; 13 Participants
Essential Hypertension
Primary: Change From Baseline to Week 6 in the Mean 24-hour Ambulatory Diastolic Blood Pressure (MADBP) — -4.10; -5.24 mm Hg
Hepatitis C, Chronic
Primary: Sustained Virologic Response (SVR) Rate in the Full Analysis Set (FAS) Population. — 21.3; 58.6; 66.5 Percentage of Participants — p=<0.0001
Respiratory Tract Infections
Primary: Body Temperature — 183; 170; 13; 2617 Participants
Influenza
Primary: Number of pH1N1 Influenza Infections as Diagnosed by PCR From Mid-turbinate Swab — 2; 4 participants — p=0.685
Diabetes Mellitus, Type 2
Primary: Change in Hemoglobin A1C (HbA1c) From Baseline to Week 12 Endpoint — -0.60; -0.80; -1.24; -1.41 percentage of glycosylated hemoglobin — p=0.0109
Hypertension
Primary: Change From Baseline to End of Study in the Mean Sitting Diastolic Blood Pressure (msDBP) — -13.07; -10.54; -5.84 mm Hg
Diabetes Mellitus, Type 2
Primary: HbA1c Change From Baseline at Week 12 — 0.25; -0.15; -0.48; -0.42 Percent — p=<0.0001
Diabetes · Diabetes Mellitus, Type 2
Primary: Change in Acetylcholine (ACh)-Mediated Forearm Blood Flow (FBF) — 4.244; -3.187; 2.164 mL/100 mL/min — p=0.0549
Staphylococcal Infection
Primary: Efficacy Adjudication Committee (EAC) Assessment of Number of Participants With Clinical Success at Test of Cure (TOC) — 45; 16; 2 Participants
Diabetes Mellitus, Type 2
Primary: HbA1c Change From Baseline to Week 24 — -0.10; -0.72 Percent — p=<0.0001
Diabetes Mellitus, Type 2
Primary: Weighted Mean Glucose (WMG) Change From Baseline at Day 28 — 0.1; -19.8; -26.1 mg/dL — p=<0.0001
Hyperphosphatemia
Primary: Number of Study-emergent Bone-related Adverse Events (AEs) — 9; 2; 1; 1 Bone-related AEs
Hepatitis C, Chronic
Primary: Sustained Virologic Response (SVR) Rate — 40.2; 66.8; 68.5; 23.1 Percentage of participants — p=<0.0001
Ovarian Suppression
Primary: Risk of Oral Contraceptive (OC) Failure Due to Less Contraceptive-mediated Ovarian Suppression. — 54; 28; 11; 12 Participants